Search Results - "Ferrarotto R"

1350P Immuno-chemotherapy alone for laryngeal cancer: ICoLP phase II trial with >2-year follow-up.

Authors: Ferrarotto, R. Hutcheson, K. Sui, D. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS840-S841. 2p.

1659P Updated pathologic responses from a pilot phase II trial of neoadjuvant immunotherapy for stage II-IV resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN).

Authors: Amit, M. Ferrarotto, R. Nagarajan, P. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS982-S982. 1p.

900P Notch inhibitor AL101 prior to surgery in patients (pts) with Notch1 activated adenoid cystic carcinoma (ACC): Safety and efficacy in a window of opportunity study.

Authors: Ferrarotto, R. McGrail, D. Mitani, Y. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS636-S636. 1p.

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.

Authors: Ferrarotto, R Eckhardt, G Patnaik, A et al.

Source: Annals of Oncology. Jul2018, Vol. 29 Issue 7, p1561-1568. 8p. 3 Charts, 3 Graphs.

903P AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes.

Authors: Ferrarotto, R. Bobbili, P. Bowles, D.W. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS575-S576. 2p.

1789P The gamma secretase inhibitor AL101 combined with other drugs for dual targeting of Notch dysregulated tumors.

Authors: Ferrarotto, R. Rauch, R. Leibovich, T. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS1222-S1222. 1p.

A Double-Blinded Analysis of Radiation Dermatitis in Patients with Advanced Oropharyngeal Cancer Treated with IMPT vs. IMRT.

Authors: Fink, K.E. Swanson, D. Ferrarotto, R. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2025 Supplement, Vol. 123 Issue 1, pS219-S220. 2p.

Subjects: Oropharyngeal cancer, Intensity modulated radiotherapy, Radiodermatitis, Proton therapy

919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut).

Authors: Ferrarotto, R. Wirth, L.J. Muzaffar, J. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS663-S663. 1p.

6598 POSTER Combination of Capecitabine and Oxaliplatin (CAPOX) is an Effective Option for the Treatment of Neuroendocrine Tumours (NET)

Authors: Ferrarotto, R. Testa, L. Riechelmann, R.R. et al.

Source: European Journal of Cancer. Sep2011 Supplement 1, Vol. 47, pS471-S471. 1p.

1018eTiP A phase I trial of RGT-61159, an oral MYB transcription factor inhibitor, for patients with relapsed/refractory (R/R) adenoid cystic carcinoma (ACC) and colorectal cancer (CRC).

Authors: Hanna, G.J. Sanz Garcia, E. Spira, A.I. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS662-S663. 2p.

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.

Authors: Gross, N. D. Miller, M. Khushalani, N. I. et al.

Source: New England Journal of Medicine. 10/27/2022, Vol. 387 Issue 17, p1557-1568. 12p.

Association between KRAS mutation and lung metastasis in advanced colorectal cancer.

Authors: Pereira, A A L Rego, J F M Morris, V et al.

Source: British Journal of Cancer. 2/3/2015, Vol. 112 Issue 3, p424-428. 5p.

Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.

Authors: McGrail, D.J. Pilié, P.G. Rashid, N.U. et al.

Source: Annals of Oncology. Sep2021, Vol. 32 Issue 9, p1194-1197. 4p.

1407P Using liquid biopsies to classify adenoid cystic carcinoma into clinically relevant subtypes.

Authors: Heeke, S. Hoff, C.O. de Sousa, L. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS863-S863. 1p.

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.

Authors: McGrail, D.J. Pilié, P.G. Rashid, N.U. et al.

Source: Annals of Oncology. May2021, Vol. 32 Issue 5, p661-672. 12p.

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.

Authors: McGrail, D.J. Pilié, P.G. Rashid, N.U. et al.

Source: Annals of Oncology. Nov2022, Vol. 33 Issue 11, p1204-1206. 3p.

A Lymph Node Immune Score (LNIS) Identifies Prognostic Immune Phenotypes Shared across Head and Neck Cancers.

Authors: Karpinets, T. Garden, A.S. Rosenthal, D.I. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2024 Supplement, Vol. 120 Issue 2, pS222-S223. 2p.

The Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamous Cell Carcinoma (OPSCC).

Authors: Wang, L. Zhang, Y. Ausat, N. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2024 Supplement, Vol. 120 Issue 2, pS123-S124. 2p.

896P Day of the week of chemotherapy (CT) during concurrent chemoradiation (CRT) for oropharyngeal squamous cell carcinoma (OPSCC).

Authors: Hoff, C.O. Feng, L. Bonini, F. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS634-S635. 2p.

Prognostic Value of Time To Progression vs. Tumor Volume Doubling Time in Patients with Adenoid Cystic Carcinoma Metastatic To The Lung.

Authors: Sousa, L.G. Lago, E. Andreazza Dal Yang, Z. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Apr2024, Vol. 118 Issue 5, pe80-e81. 2p.